Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK).

Following the acquisition of Luminex, the company acquired five additional production plants located in the United States (Austin, Madison, Chicago, and Seattle) and in Canada (Toronto).

The Group is mainly active in the development, production and marketing of diagnostic tests used by the medical community to assess a patient's values, understand their state of health or monitor the progression of a disease.

Diasorin also focuses on the development of research and laboratory kits in the field of molecular diagnostics, particularly specializing in the infectious diseases sector with tests that use different matrices including blood, cerebrospinal fluid, cutaneous and mucus swabs.

[2][3] Diasorin focuses its efforts on several fields of immunodiagnostics: infectious diseases, bone and mineral, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmunity and brain and cardiac markers.

In molecular diagnostics, Diasorin offers proprietary platforms that cover the three phases of the testing process: extraction, amplification and detection.

[20] In September 2020 Diasorin and MeMed started a strategic partnership for the development and commercialization of a diagnostic solution based on the patients' immune response that can differentiate between bacterial and viral infections.

[21] In April 2021, in partnership with QIAGEN, Diasorin launched in countries accepting the CE Mark the LIAISON LymeDetect test for the early diagnosis of Lyme Borreliosis, based on the QuantiFERON technology.

[34][35] On October 26, Diasorin announced the obtainment of the CE mark for the launch of the new Liaison Sars-Cov-2 Ag antigen test, capable of detecting COVID-19 on symptomatic patients and determining their viral load.

The test is therefore able to detect the full variety of the natural immune response to the virus reducing the risk of false negative results.

On April 6, 2021, Diasorin launched in countries accepting CE Mark a new Point-of-Care immunodiagnostic platform, the LIAISON IQ, developed in partnership with Lumos Diagnostics together with a first test to detect antibodies against SARS-CoV-2.

[38] The research team of about 200 people is dedicated to the development of solutions for specialized tests to support doctors and laboratory managers in the processing of diagnoses of even niche diseases.

The areas of Diasorin's offer for analysis kits in the specialty immunodiagnostics sector are the following: • Infectious diseases • Gastrointestinal infections • Bone and mineral metabolism • Endocrinology • Hypertension • Oncology • Onco-hematology • Autoimmunity In particular, in the field of molecular diagnostics, Diasorin has focused its research on the area of infectious diseases, with tests based on different matrices—including blood, cerebrospinal fluid, skin, and mucocutaneous swabs.

The LIAISON XS analyzer, currently available in European countries, is designed for analysis laboratories with low-medium throughput needs that can take advantage of this new platform for specific needs related to specialty tests.

[41] In 2019 Diasorin generated revenues (706.3 million euros) in Europe and Africa for 46.1%, in the United States and Canada for 29.1%, in Asia and Oceania for 19.0%, in America Latin for 6.3%.